Takeda Presents Clinical Data on Ulcerative Colitis Treatment at UEG Meeting

Takeda presented new findings from the VERDICT Phase 4 clinical trial at the United European Gastroenterology meeting. The trial showed that treating adults with intravenous ENTYVIO to achieve corticosteroid-free disease clearance resulted in a nearly 70 percent reduction in the risk of ulcerative colitis-related complications compared to symptomatic remission alone. Over half of patients who met the assigned treatment target reached disease clearance at Week 16.

The results provide prospective, randomized evidence that achieving deeper levels of remission is a clinically relevant target for treating moderate to severe ulcerative colitis. This suggests that addressing both visible and microscopic inflammation may ameliorate the long-term burden of the disease.